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Abstract
Aims/hypothesis Skin fluorescence (SF) is a non-invasive
marker of AGEs and is associated with the long-term compli-
cations of diabetes. SF increases with age and is also greater
among individuals with diabetes. A familial correlation of SF
suggests that genetics may play a role. We therefore per-
formed parallel genome-wide association studies of SF in
two cohorts.
Methods Cohort 1 included 1,082 participants, 35–67 years of
age with type 1 diabetes. Cohort 2 included 8,721 participants
without diabetes, aged 18–90 years.
Results rs1495741 was significantly associated with SF in
Cohort 1 (p<6×10−10), which is known to tag the NAT2
acetylator phenotype. The fast acetylator genotype was asso-
ciated with lower SF, explaining up to 15% of the variance. In
Cohort 2, the top signal associated with SF (p=8.3×10−42)
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was rs4921914, also in NAT2, 440 bases upstream of
rs1495741 (linkage disequilibrium r2=1.0 for rs4921914 with
rs1495741). We replicated these results in two additional
cohorts, one with and one without type 1 diabetes. Finally,
to understand which compounds are contributing to the
NAT2–SF signal, we examined 11 compounds assayed from
skin biopsies (n=198): the fast acetylator genotype was asso-
ciated with lower levels of the AGEs hydroimidazolones of
glyoxal (p=0.017).
Conclusions/interpretation We identified a robust association
between NAT2 and SF in people with and without diabetes.
Our findings provide proof of principle that genetic variation
contributes to interindividual SF and that NAT2 acetylation
status plays a major role.
Keywords Acetylation . Genome-wide association study .
NAT2 . Skin autofluorescence . Skin fluorescence . Skin
intrinsic fluorescence
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CAD Coronary artery disease
EDIC Epidemiology of Diabetes Interventions and
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UKPDS UK Prospective Diabetes Study
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Introduction
AGEs accrue in the body during ageing, and their formation
and accumulation are significantly accelerated in diabetes [1].
AGE formation is a multistep process in which the non-
enzymatic glycation of proteins is followed by the formation
of stable adducts and cross-links, leading to structural and
functional tissue impairment [2]. Among people without
diabetes, additive genetic effects explain 74% of the pop-
ulation variance of serum-determined AGEs, but the loci
are unknown [3].
Skin collagen undergoes glycation and glycoxidation
[1]. Given that skin collagen has a half-life of 10–15 years
[4], skin AGEs capture decades-long glycaemia [5, 6].
AGEs in skin biopsies predict microvascular complica-
tions of type 1 diabetes, independent of HbA1c level
[5–7]. However, skin biopsies are impracticable for large
studies.
The measurement of skin fluorescence (SF) using op-
tical spectroscopy, corrected for pigmentation, offers a
non-invasive measurement of AGEs [8–10]. SF reflects
glycaemia in type 1 and type 2 diabetes [8, 11–13] and
can screen for abnormal glucose tolerance [14]. SF has
been associated with macro- and microvascular complica-
tions in type 1 diabetes, independent of long-term HbA1c
level [15–18]. In addition, SF is significantly associated
with mortality from CHD in diabetes, independent of
other risk factors [11, 19].
When adjusted for age and HbA1c level, SF is corre-
lated (r=0.43, p=0.01) between siblings discordant for
type 1 diabetes, suggesting genetic contributions [20]. A
twin study has shown that lens fluorescence is significant-
ly heritable [21]. However, the specific genetic determi-
nants of SF are unknown. Given that SF is greater in
people with than without diabetes [8], we performed
genome-wide association studies (GWASs) in two parallel
discovery cohorts to identify loci associated with SF in
participants with type 1 diabetes and without diabetes.
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Methods
Design
The first cohort included 1,082 participants with type 1 dia-
betes from the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) study (Table 1, electronic supplementary ma-
terial [ESM] Table 1) [12]. The second cohort consisted of
8,721 participants without diabetes from the LifeLines Cohort
Study (Table 2, ESM Table 2) [22]. Two additional cohorts
contributed to replication of the results (ESMTables 3–5). The
first of these cohorts included participants with type 1 diabetes
from the Wisconsin Epidemiologic Study of Diabetic
Retinopathy (WESDR, n=202) [23] and the second included
an older cohort of participants from the LonGenity study
(n=515) [24], consisting primarily of participants without
diabetes. All individuals were of European descent. These
studies were approved by the institutional review boards of
all the participating institutions, and informed consent was
obtained from all the participants.
Discovery cohort 1: DCCT/EDIC
Participants At a point 16–17 years after the close-out of the
DCCT [25], SF was assessed in 1,082 active participants who
had GWAS data [12].
Measurement of SF Skin intrinsic fluorescence (SIF),
corrected for factors that affect light scattering and absorption,
was measured from the underside of the left forearm using the
SCOUT DS SF spectrometer (VeraLight, Inc., Albuquerque,
NM, USA) [12, 15]. SIF excited with a light-emitting diode
(LED) centred at 375 nm, and emission detected over 435–
655 nm (with the reflectance adjusted by the dimensionless
exCitation and emission exponents, kx=0.6, km=0.2,
respectively), referred to as SIF1, was the primary outcome
[15, 18]. In secondary analyses, we examined SIFs measured
using excitation LEDs centred at 405 nm, 416 nm, 435 nm and
456 nm (SIF2–SIF15; ESM Table 6).
Discovery cohort 2: LifeLines
Participants The LifeLines observational follow-up study in-
cludes a random sample of 165,000 inhabitants of three north-
ern provinces of the Netherlands, who have been recruited
since 2006 [22]. For this analysis, we included participants
18–90 years of age who had had both GWAS and AGE
Reader (DiagnOptics Technologies BV, Groningen, the
Netherlands) measurement of skin autofluorescence
(SAF) collected from 2006 to 2012. For the GWAS,
we excluded participants who were known to have type
1 (n=12) or type 2 diabetes and/or had a fasting blood
plasma glucose level >7.0 mmol/l (n=318), leaving
8,721 individuals. We also examined participants with
Table 1 DCCT/EDIC participant characteristics for those with GWAS
and SIF measures (n=1,082) taken at the time of SIF assessment shown
separately by the original DCCT randomised treatment groups
Variable Former INT Former CON
n=555 n=527
Demographic characteristics
Male sex 294 (53%) 285 (54%)
Age (years) 52.0±7.0 51.0±6.9
Diabetes duration (years) 30.1±4.9 29.5±4.8
Primary cohort assignmenta 264 (48%) 270 (51%)
Skin tone (AU) 263.9±39.5 259.4±42.9
Clinic latitude (>37° N)b 407 (73%) 393 (75%)
Never smokerc 335 (60%) 318 (60%)
Former smokerc 143 (26%) 140 (27%)
Current smokerc 77 (14%) 69 (13%)
Any eGFR <60 ml min−1 1.73 m−2
to date (yes)
36 (7%) 41 (8%)
Glycaemic exposure
DCCT eligibility HbA1c
% 9.1±1.6 8.9±1.6
mmol/mol 76±18 74±18
DCCT mean HbA1c
% 7.2±0.8 9.0±1.2
mmol/mol 55±9 75±13
EDIC mean HbA1c
% 8.0±1.1 7.9±1.0
mmol/mol 64±12 63±11
Time-weighted mean HbA1c
d
% 8.0±0.9 8.4±0.9
mmol/mol 64±10 68±10
SIF1 (LED 375 nm, kx 0.6, km 0.2) (AU)
e 3.1±0.2 3.1±0.2
SIF12 (LED 435 nm, kx 0.4, km 0.9) (AU)
e 0.94±0.24 0.94±0.25
Data are n (%) or mean ± SD
a Two cohorts were recruited at the DCCT baseline: a primary cohort
(n=726) of participants with a duration of diabetes of 1–5 years, no
retinopathy and a urinary AER <40 mg/24 h at baseline; and a secondary
cohort (n=715) of participants with a duration of diabetes of 1–15 years,
mild to moderate non-proliferative retinopathy and a urinary
AER ≤200 mg/24 h at baseline
b Clinic latitude was categorised as a binary variable, with clinics located
above 37° N latitude designated as northern clinics (n=21) and those
below 37° N latitude assigned as southern clinics (n=7)
c Smoking status was defined as ‘Never smoker’ (≤100 cigarettes in a
participant’s lifetime), ‘Former smoker’ (quit ≥1 year ago) or ‘Current
smoker’ (currently smoking or smoking within the last year)
d Time-weighted mean HbA1c is calculated by summing (DCCT eligibil-
ity HbA1c×duration of diabetes at DCCT baseline), (DCCT mean
HbA1c×years of follow-up in DCCT) and (EDIC mean HbA1c×years
of follow-up in EDIC) and dividing by the total duration of diabetes
e loge transformed
CON, conventional group; INT, intensive group
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type 2 diabetes (Table 2), either previously known (n=216) or
newly diagnosed by fasting blood plasma glucose level
(>7.0 mmol/l, n=102) in secondary analyses.
Measurement of SF SAF was measured with the AGE Reader
[8, 13]. Similar to SIF1, the excitation light source used a peak
at 370 nm. The spectrometer measures emitted and reflected
light over 420–600 nm and 300–420 nm, respectively. AGE
Reader software (v2.3) calculates SAF from the ratio between
the emitted and the reflected light, multiplied by 100
(expressed as arbitrary units [AU]), taking skin colour into
account [26]. For each SAF value, measurements were carried
out at three different sites of the same forearm, and the mean
was used for the analysis.
Skin collagen ancillary substudy
Skin biopsies were obtained on a subset of DCCT participants
(n=216) at close-out, and 11 AGEs and collagen cross-linking
variables were determined [5, 6].
Genotyping
The Illumina 1 M beadchip assay (Illumina, San Diego, CA,
USA), which underwent extensive quality control [27], was
used in the DCCT/EDIC cohort for genome-wide genotyping.
Quality control checks were applied to ensure that there were
no sample mix-ups, and participants were excluded if they
were determined to be admixed using population genetic
approaches [28]. A total of 841,342 autosomal single nucleo-
tide polymorphisms (SNPs) with a minor allele frequency
(MAF) >1% were subsequently analysed. In addition,
1,609,583 (INFO ≥ 0.30) imputed autosomal SNPs using
release 22 Phase II Centre d'Etude du Polymorphisme (Utah
residents with northern and western European ancestry)
(CEU) HapMap data (IMPUTE v2; https://mathgen.stats.ox.
ac.uk/impute/impute.html) were used for analysis.
In the LifeLines cohort, Illumina CytoSNP 12v2 was used
for genome-wide genotyping. Genotyped SNPs with an
MAF <0.01, a call rate ≤95% and a Hardy–Weinberg equilib-
rium (HWE) p value <10−4 were excluded. A total of 837,184
genotyped or imputed SNPs (allelic R2≥0.80) using HapMap
(release 24) CEU (Beagle, v3.1.0) were used for GWAS.
Sample relatedness was assessed by participant self-report
and population genetic approaches, and the sample with the
highest genotyping quality was included for first-degree rela-
tives. Samples were further excluded due to discrepancy in
sex, an average heterozygosity >4SD from the mean and non-
European ancestry assessed using identical-by-state analysis
and Eigenstrat (http://genetics.med.harvard.edu/reich/Reich_
Lab/Software.html) [29].
Statistical analysis
GWAS The primary outcome variable for GWAS in the
DCCT/EDIC group was loge SIF1. Since genetic variants
may be associated with SF through effects on factors associ-
ated with SF, such as smoking or HbA1c level, we first
performed a univariate GWAS of SIF1 using genotyped SNPs
by linear regression (Model 1 [M1]). To increase the power to
detect loci associated with SIF1 by explaining additional
variance in the trait, a second GWAS adjusted for age, sex,
smoking status, skin tone, clinic latitude and ever having had
an estimated GFR (eGFR) <60 ml/min/1.73 m2 (Model 2
[M2]). Finally, a third GWAS was conducted adjusting for
the same covariates in M2 with the addition of HbA1c
measured as follows: at the DCCT eligibility screening,
as the mean during the DCCT and as the mean during
the EDIC study (M3). DCCT/EDIC Model 3 [M3] was
also analysed using imputed SNPs as dosages. To deter-
mine whether there were any independent signals, a
GWAS conditioning on the top SNP observed from the
GWAS was conducted using M1.
In the LifeLines cohort, the primary outcome variable for
GWAS was SAF. We first performed an analysis without
covariates (M1). Next, we corrected for age, sex and smoking
status (M2). Finally, we added BMI, fasting plasma glucose
level, HbA1c level, Cockcroft–Gault eGFR and principal
Table 2 LifeLines Cohort Study participant characteristics of those with
GWAS and SAF measures available (n=9,039)
Variable Individuals without
diabetes (n=8,721)
Individuals with
type 2 diabetes
(n=318)
Demographic characteristics
Male sex 3,590 (41%) 168 (53%)
Age (years) 49.0±11 58.9±10.8
BMI (kg/m2) 26.4±4.2 30.5±5.4
Current smoker 1,922 (22%) 55 (17%)
Creatinine (μmol/l) 74±14 78±36
eGFR Cockcroft–Gault
(ml min−1 1.73 m−2)
113±31 118±45
Glycaemic exposure
Fasting plasma glucose
(mmol/l)
5.0±0.5 7.9±2.3
HbA1c
% 5.5±0.3 6.8±1.1
mmol/mol 37±3.3 52±12
Lipids
Total cholesterol (mmol/l) 5.1±1.0 4.7±1.2
LDL-cholesterol (mmol/l) 3.3±0.9 2.9±1.0
HDL-cholesterol (mmol/l) 1.44±0.38 1.23±0.32
Triacylglycerol (mmol/l) 1.05 (0.76–1.48) 1.41 (1.04–2.15)
SAF (AU) 2.04±0.44 2.45±0.59
Data are shown as n (%), mean ± SD, or median (interquartile range)
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components (PCs) to M2 (M3). An additive model was used
in all models. A p-value <5×10−8 was required for genome-
wide significance in each discovery cohort.
Using METAL (v2011-03-25; www.sph.umich.edu/csg/
abecasis/Metal/download/), we also ran a meta-GWAS
for M3 using genotyped or imputed SNPs from the
DCCT/EDIC and LifeLines studies using weights proportional
to √n on z scores [30].
Characterisation of rs1495741 in the DCCT/EDIC Further
analyses were conducted using DCCT/EDIC M1 including
adjustment for PCs, and testing for deviation from an additive
genetic model by including a heterozygous indicator to a
model with rs1495741 coded additively. We also examined
the association of rs1495741 with SIF2–SIF15. The heteroge-
neity of rs1495741 effects was assessed by including
rs1495741–covariate interactions. rs1495741 was tested for
association with glycaemia measured by HbA1c level during
the DCCT and EDIC studies, and with capillary glucose
during the DCCT, using linear regression adjusted for DCCT
treatment group. The association with the presence of diabetes
complications was tested using logistic regression adjusted for
covariates in M2 and M3 (each with and without adjustment
for any eGFR <60 ml/min/1.73 m2). Logistic regression was
also used to test rs1495741 for an association with the risk of
hypoglycaemia during the DCCT, comparing participants
with one or more episodes of hypoglycaemia requiring
assistance with those without, and similarly comparing
participants with hypoglycaemia resulting in coma with
those without. Linear mixed models were used to determine
the association with lipids measured annually during the
DCCT.
Skin biopsy ancillary substudy in the DCCT cohort Multiple
linear regression adjusting for age, duration of diabetes and
randomised treatment group in the DCCT was used to deter-
mine whether rs1495741 was associated with AGEsmeasured
from skin biopsies [5, 6].
Characterisation of rs4921914 in the LifeLines cohort
rs4921914 was tested for an association with HbA1c using
linear regression adjusted for age, sex, smoking status, BMI,
Cockcroft–Gault eGFR, fasting plasma glucose level and PCs.
To test the association with fasting plasma glucose, the
same analysis was used, but was adjusted for HbA1c
instead of fasting plasma glucose level. The association
of rs4921914 with lipid variables was adjusted for all
the above covariates with lipid levels adjusted for statin
use [31].
Testing rs4921914 among type 2 diabetes in the LifeLines
cohort Linear regression was used to test whether
rs4921914 was associated with SAF in 318 participants with
type 2 diabetes in the LifeLines study. To determine
whether the association for rs4921914 differed between
participants with type 2 diabetes (n=318) and those with-
out diabetes (n=8,721), we added an rs4921914–diabetes
interaction.
PLINK (v1.07) (http://pngu.mgh.harvard.edu/~purcell/
plink/) [32] was used for GWASs of genotyped SNPs in
DCCT/EDIC, PLINK (v1.90alpha) in LifeLines, R (v2.15.2;
www.r-project.org/) for imputed SNPs and for the generation
of plots and calculation of genomic control lambda
(GenABEL; www.genabel.org/). SAS (v9.2; Cary, NC,
USA) and STATA (v.11; College Station, TX, USA) were
used for all analyses at the top SNP in the DCCT/EDIC and
LifeLines cohorts, respectively.
Results
Discovery GWAS 1: DCCT/EDIC
The GWAS of SIF1 from the DCCT/EDIC cohort identified a
significant association with rs1495741 (p=6.1×10−10;
Table 3), 14 kb downstream of NAT2 (Fig. 1a, ESM
Fig. 1a). rs1495741 is associated with the in vitro measured
NAT2 acetylator phenotype and tags haplotypes that define the
acetylator status with 99% sensitivity and 95% specificity in
white individuals [33–35]. Examination of the rs1495741
allele intensity cluster plot showed a clear separation of geno-
types (ESM Fig. 2, G-allele MAF=0.22, chromosome 8p22,
build 36 position 18,317,161), with no significant deviation
from HWE (p=0.75). The association with SIF1 was not
materially different after adjusting for the first three PCs (p
for M1=5.5×10−10). Upon adjusting for covariates in M2 and
M3, no additional genome-wide significant loci were identi-
fied (ESM Fig. 1b, c, ESM Fig. 3, Table 3, GWAS results
available from dbGaP: ftp://ftp.ncbi.nlm.nih.gov/dbgap/
studies/phs000086/analyses/). Results from an analysis
conditional on rs1495741 did not identify any independent
signals that were significant genome-wide (data not shown).
SIF1 was lower with each copy of the fast acetylator G-allele
(Fig. 1b) and there was no deviation from an additive model
(p=0.69). Results from M1 show that rs1495741 explains 3.
5% of the variance in SIF1, and explains an additional 3% of
the variance when added to the covariates in M3, which
explains 33% of the variance in SIF1 [12].
We also examined the association for rs1495741 with
SIF2–SIF15 and observed the strongest relationship for
SIF12 (p for M3=2.9×10−49), explaining 15.0% of the vari-
ance (Table 3, ESM Table 6). Importantly, rs1495741 was still
significantly associated with SIF1 (p=4.04×10−19) after
adjusting for SIF12, suggesting that the effect on SIF1 is
independent of the effect on SIF12.
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Table 3 Associations of rs1495741 with SIF, glycaemia, complications of type 1 diabetes, AGEs and lipids in the DCCT/EDIC cohort
Variable n (AA/AG/GG) β±SE/OR (95% CI) p value
SIF
SIF1 M1 (AU) 1,081 (649/380/52) −0.065±0.010 6.1×10−10
SIF1 M2 (AU) 1,081 (649/380/52) −0.059±0.009 9.3×10−12
SIF1 M3 (AU) 1,081 (649/380/52) −0.060±0.008 1.7×10−12
SIF12 M3 (AU) 1,081 (649/380/52) −0.16±0.01 2.9×10−49
Glycaemia
HbA1c updated mean (%)
a,b 1,081 (649/380/52) −0.0003±0.006 0.95
Mean 7-point capillary blood glucose profile (mmol/l)a 1,303 (782/458/63) 0.010±0.009 0.23
T1DM complicationsc
Moderate non-proliferative DR or worse 1,081 (649/380/52) 1.20 (0.97, 1.49) 0.09
Sustained AER >30 mg/24 h 1,081 (649/380/52) 0.89 (0.64,1.24) 0.47
Presence of confirmed clinical neuropathy 1,018 (610/359/49) 1.02 (0.80, 1.30) 0.90
Presence of cardiac autonomic neuropathy 1,046 (629/365/52) 0.90 (0.71, 1.14) 0.37
CAC >0 Agatston units 978 (582/348/48) 1.07 (0.83, 1.39) 0.60
CAC >200 Agatston units 978 (582/348/48) 0.81 (0.50, 1.30) 0.38
Hypoglycaemia
Hypoglycaemia requiring assistance 1,303 (782/458/63) 0.97 (0.81, 1.17) 0.78
Hypoglycaemia resulting in coma or seizure 1,303 (782/458/63) 0.89 (0.72, 1.09) 0.25
Skin biopsy AGEs
Pepsin soluble collagen (% solubility)a 198 (132/61/5) 0.08±0.06 0.13
Acid soluble collagen (% solubility)a 198 (132/61/5) 0.01±0.07 0.87
Nε-Carboxymethyl-lysine (pmol/mg collagen) 196 (131/60/5) −8.84±17.4 0.61
Fluorescence (AU)a 198 (132/61/5) −0.03±0.03 0.27
Furosine (pmol/mg collagen)a 195 (129/61/5) 0.001±0.03 0.97
Pentosidine (pmol/mg collagen)a 194 (130/59/5) −0.03±0.03 0.31
Carboxyethyl-lysine (pmol/mg)a 196 (130/61/5) 0.17±0.09 0.059
Glucosepane (nmol/mg)a 198 (132/61/5) 0.01±0.09 0.73
Hydroimidazolones of methylglyoxal (nmol/mg)a 198 (132/61/5) 0.05±0.007 0.43
Fructose-lysine (nmol/mg)a 198 (132/61/5) 0.02±0.04 0.60
G-H1 (pmol/mg)b 197 (131/61/5) −0.62±0.26 0.017
Lipidsd
Total cholesterol (mmol/l)a 1,303 (782/458/63) 0.004±0.008 0.57
LDL-cholesterol (mmol/l)e 1,303 (782/458/63) 0.01±0.009 0.27
HDL-cholesterol (mmol/l)a 1,303 (782/458/63) −0.03±0.01 0.008
Triacylglycerol (mmol/l)a 1,303 (782/458/63) 0.04±0.02 0.01
Data shown are β±SE from linear regression or mixed linear models for continuous outcomes, or OR (95% CI) from logistic regression for the SNP
effect, with each copy of the G-allele coded additively
a Loge transformed
b Time-weighted mean HbA1c is calculated by summing (DCCT eligibility HbA1c×duration of diabetes at DCCT baseline), (DCCT mean
HbA1c×years of follow-up in DCCT) and (EDIC mean HbA1c×years of follow-up in EDIC) and dividing by the total duration of
diabetes
c Results shown are from logistic regression analyses adjusted for M2 covariates
d The linear mixed model analyses of lipids were adjusted for visit, visit2 , DCCT treatment group, DCCT baseline indicator and DCCT treatment group ×
DCCT baseline indicator interaction Random effects were included for the intercept and visit, visit2
e Square root transformed
CAC, coronary artery calcium; DR, diabetic retinopathy; T1DM, type 1 diabetes
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Discovery GWAS 2: LifeLines
The top SAF association signals observed in the LifeLines
cohort were 47 SNPs that were also in the NAT2 region (M3;
p<5×10−8) (Table 4, ESM Figs 4 and 5). The top signal
(LifeLines M3, p=1.0×10−60, R2=2.1%) was rs4921914,
440 bases upstream of rs1495741 (ESM Fig. 6). According
to HapMap phase 2 CEU (release 22), rs4921914 is in perfect
linkage disequilibrium (LD; r2=1.0) with rs1495741 (C- and
G-alleles, respectively). rs4921914 was imputed with allelic
R2=0.81 (MAF=0.19 for the C-allele) and showed no
deviation from HWE (p=0.36). The association was in the
same direction as observed in the DCCT/EDIC group.
We did not identify any additional genome-wide significant
loci after meta-GWAS (ESM Figs 7–8).
Heterogeneity of rs1495741 effect on SF
In the DCCT/EDIC cohort, rs1495741 was not significantly
associated with any of the covariates in M2 (p>0.05, data not
shown). There was no heterogeneity of rs1495741 on SIF1
(ESMTable 7), with the exception of the updatedweightedmean
HbA1c levels for the DCCT/EDIC, which approached nominal
significance (p for the SNP*HbA1c interaction=0.058). When
analysing the effect of rs1495741 separately by the median
updated weighted mean HbA1c level for the DCCT/EDIC
(8.07%), rs1495741 was stronger among participants with
HbA1c levels greater than median (β±SE=−0.075±0.01,
p=4.7×10−7) compared with those below the median
(β±SE=−0.054±0.01, p=1.2×10−4). In the LifeLines group,
no significant SNP×HbA1c interaction was observed among
the non-diabetic participants (p=0.28). However, there was a
significant heterogeneity of rs4921914 by age (p=0.03).
Biochemical measures and complications of type 1 diabetes
In the DCCT/EDIC cohort, rs1495741 was not associated
with updated weighted mean HbA1c up to the time of SIF
measurement (p=0.95; Table 3). In participants without dia-
betes in the LifeLines cohort, rs4921914 was also not associ-
ated with HbA1c (p=0.36) or fasting plasma glucose (p=0.36)
level (Table 4). Furthermore, rs1495741 was not associated
Fig. 1 (a) Regional plot of a 300 kb region surrounding rs1495741
(p=1.7×10−12) showing genotyped and imputed SNPs plotted with their
(–log10) p values from the DCCT/EDIC cohort (M3) on the left y-axis and
their genomic position (NCBI Build 35; www.ncbi.nlm.nih.gov/
mapview/stats/BuildStats.cgi?taxid=9606&build=3) on the x-axis. Gene
annotations (Genome Browser; http://genome.ucsc.edu/) are shown
above the x-axis. Estimated recombination rates (HapMap II release 22;
http://hapmap.ncbi.nlm.nih.gov/) are plotted on the right y-axis. For
genotyped SNPs, the LD values shown were calculated based on
pairwise r2 values for rs1495741 from the DCCT/EDIC cohort, and for
imputed SNPs are based on r2 values from HapMap phase II (Nov08,
release 24, on NCBI B36 assembly, dbSNP b126). The blue diamond
indicates rs1495741 and the SNPs are coloured based on their LD with it
(red, r2≥0.8; orange, 0.5≤r2<0.8; yellow, 0.2≤r2<0.5; white, r2<0.2);
(www.broadinstitute.org/diabetes/scandinavs/figures.html). (b)
Beeswarm plot showing level of unadjusted loge SIF1 for each
participant in the DCCT/EDIC cohort according to their rs1495741
genotype, with the mean ± SD shown above the x-axis
Table 4 Associations of rs4921914 with SAF, glycaemia and lipids in
the LifeLines Cohort Study
Variable n β±SE p value
SAF
M1 (AU) 8,721 −0.1149±0.0084 8.3×10−42
M2 (AU) 8,721 −0.1154±0.0069 8.2×10−62
M3 (AU) 8,675 −0.1148±0.0069 1.0×10−60
Glycaemia
Fasting plasma glucose
(mmol/l)
8,698 −0.009±0.009 0.36
HbA1c (%) 8,689 −0.005±0.006 0.36
Lipids
Total cholesterol (mmol/l) 8,706 −0.011±0.019 0.56
LDL-cholesterol (mmol/l) 8,706 −0.004±0.017 0.80
HDL-cholesterol (mmol/l) 8,705 −0.00014±0.007 0.98
Triacylglycerol (mmol/l)a 8,706 0.019±0.009 0.06
Data shown are β±SE from linear regression for the SNP effect with each
copy of the C-allele coded additively
a Loge transformed
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with the mean of 7-point capillary blood glucose profiles
measured during the DCCT (p=0.23). In the DCCT/EDIC
cohort, rs1495741 was not associated with any microvascular
complications or markers of macrovascular complications in
models adjusted for M2 and/or M3 covariates (either with or
without adjusting for any eGFR<60 ml/min/1.73 m2), or with
hypoglycaemia (Table 3).
Since rs1495741 has been associated with lipids [36], we
examined its association with repeated measures of lipids
during the DCCT. rs1495741 was nominally associated with
triacylglycerol (p=0.01) and HDL-cholesterol (p=0.008)
values (Table 3). The effect of rs1495741 on SIF1 was un-
changed after adjusting for time-weighted mean triacylglycerol
(p=1.8×10−12) or HDL-cholesterol (p=9.1×10−13) on M3. In
the LifeLines cohort, no association could be demonstrated
(Table 4), although the power to detect an effect on triacylglyc-
erol and total cholesterol [36] was 61% and 31%, respectively.
Skin biopsy ancillary substudy in the DCCT cohort
Of the 11 AGEs and collagen cross-linking variables mea-
sured in the skin biopsies, rs1495741 was associated only with
hydroimidazolones of glyoxal (G-H1; p=0.017; Table 3), in
the same direction as the association with SF.
SAF among individuals with type 2 diabetes in the LifeLines
cohort
rs4921914 was significantly associated (β±SE=−0.20±0.06,
p=5.2×10−4) with SAF in participants with type 2 diabetes
and explained 3.4% of the variance in SAF. The difference in
the SNP effect between the participants with and without type
2 diabetes was p=0.07, with a stronger association observed
in those with type 2 diabetes.
Replication in the WESDR and LonGenity cohorts
In a second cohort of type 1 diabetes participants, rs1495741
(G-allele MAF=25%, HWE p=0.51) was associated with
SIF1 (β±SE=−0.06±0.02, p for the multivariate model=
0.002, r2 for the univariate model=5.3%), in the same direc-
tion of effect as in the discovery cohorts (Table 5). The effect
of rs1495741 on SIF1 did not differ according to smoking
status (p=0.54). rs1495741 was also associated with SIF14
(β±SE=0.10±0.02, p for the multivariate model=6.0×10−5,
r2 for the univariate model=9.2%). Finally, rs1495741 was
not associated with repeated measures of HbA1c in linear
mixed models (p=0.53), or time to mild (p=0.28) or severe
diabetic retinopathy (p=0.18).
rs1495741 (G-allele MAF=18%, HWE p=0.92) was not
significantly associated with SIF1 (β±SE=−0.01±0.007,
p=0.09; Table 5) in LonGenity, an older cohort (mean ± SD
age 75±6 years) of participants predominantly without
diabetes (89%). However, consistent with the DCCT/EDIC
and WESDR cohorts, rs1495741 was associated with SIF14
(β±SE=−0.02±0.007, p=0.0004) in the same direction.
Discussion
Most GWASs of quantitative traits use blood-based measures,
for which levels may vary widely within a person over time
due to clearance predominantly by the kidneys and liver. SF,
on the other hand, provides a measure of long-term tissue
damage associated with ageing [8, 9] as well as with
decades-long blood glucose levels in people with diabetes
[12], given the long half-life of skin collagen [4]. Using a
GWAS, we identified rs1495741 located 14 kb downstream of
NAT2 to be associated with SF in individuals with type 1
diabetes, and the same signal (rs4921914, r2=1.0) was ob-
served in a separate discovery cohort of individuals without
Table 5 Associations of rs1495741with SIF1, SIF14 and other measures
in the WESDR and LonGenity cohorts
Variable n β±SE p value
WESDR
SIF1 (AU)a,b 200 −0.06±0.02 0.002
SIF14 (AU)a,c 202 −0.10±0.02 6.0×10−5
HbA1c (%)
c 601 0.05±0.08 0.53
Mild DRd 603 0.08±0.08 0.28
Severe DRd 603 0.13±0.10 0.18
LonGenity
SIF1 (AU)e,f 515 −0.01±0.007 0.09
SIF14 (AU)e,f 515 −0.02±0.007 0.0004
Data shown are β±SE from linear regression for the SNP effect with each
copy of the G-allele coded additively
a Loge transformed
b Two outliers (one at each tail) were observed for SIF1 in the WESDR
cohort and excluded from the analysis, leaving 200 participants for
analysis of SIF1. The SNP was examined for association with SIF1 and
SIF14 adjusting for age, sex, smoking status, skin tone, eGFR <60mlmin−1
1.73 m−2 and HbA1c concurrent with the SIF measure
c Associations of the SNP with repeated measures of HbA1c were
analysed using linear mixed models adjusted for time and random
intercept
d Complementary log–log models for interval-censored survival times
were used to examine associations with mild diabetic retinopathy (DR),
adjusted for age at baseline, sex, duration of diabetes at baseline, time-
dependent updated mean HbA1c and time-dependent BMI, and severe
DR (adjusted for the same variables except for time-dependent BMI).
e log10 transformed
f Association for the SNP with SIF1 and SIF14 was examined adjusting
for age, sex, skin tone, smoking status, eGFR <60 ml/min/1.73 m2 and
presence of diabetes
DR, diabetic retinopathy
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diabetes. We further replicated the association for SF in indi-
viduals with type 1 and 2 diabetes. In addition, the signal
observed for rs1495741 with SIF14 was also replicated in the
WESDR and LonGenity populations. In the DCCT/EDIC
cohort, rs1495741 explains 3.5% of the variance in SIF1 and
appears to be tagging NAT2, with no signals observed in the
neighbouring NAT1. In all four studies, each copy of the fast
acetylator allele was associated with less SF.
The association of NAT2 with SF was robust across differ-
ent populations and different measures of SF both within and
across studies. First, we observed the association in individuals
both with and without type 2 diabetes in the LifeLines group, as
well as in those with type 1 diabetes in the DCCT/EDIC and
WESDR cohorts. There was suggestion that a stronger effect of
NAT2 on SFmight exist in individuals with type 2 diabetes than
in those without diabetes. Similarly, the effect of NAT2 on SIF
was stronger in participants who had higher HbA1c levels in
comparison to those with lower HbA1c levels in the
DCCT/EDIC population. However, no significant SNP*HbA1c
interaction was observed among non-diabetic participants in the
LifeLines group. Second, NAT2 was strongly associated with
SF excited across the range of 375–456 nm in the DCCT/EDIC
group, with the strongest effect observed for excitation at
435 nm (SIF12). Finally, NAT2 was the top signal observed in
both discovery GWAS cohorts, despite using different SF de-
vices. Indeed, both the SCOUT DS and the AGE Reader, used
in the LifeLines study, have been shown to correlate with skin
biopsy-determined AGEs such as pentosidine [8, 9].
Although SF has been associated with HbA1c level in
people with diabetes [8, 11, 12], rs1495741 was not associated
with glycaemia in people either with or without diabetes in our
cohorts. However, in the Meta-Analyses of Glucose and
Insulin-related traits Consortium (MAGIC; http://www.
magicinvestigators.org), a large meta-GWAS of more than
46,000 non-diabetic adults of European descent, the G-allele
of rs1495741 was associated with higher HbA1c (p=0.003)
[37] and fasting plasma glucose (p=0.03) values [38]. Both
associations were in the opposite direction to the effect of
NAT2 on SF (ESM Table 8). Thus, a small effect for
rs1495741 on glycaemic traits in non-diabetic individuals
may exist and may be observed only in very large analyses.
Despite the association of SF with the complications of
type 1 diabetes [15–18, 39], rs1495741 was not associated
with coronary artery calcium, nephropathy, neuropathy or
retinopathy in the DCCT/EDIC group, or with time from
baseline to either mild or severe retinopathy in the WESDR
cohort. The non-significant association with these outcomes is
due to the low power to detect small effects, since we
have good power for detecting an OR >1.50 for a sustained
AER >30 mg/24 h with α=0.05 [15]. In line with this, the
rs1495741 G-allele has previously been associated (OR 1.06,
p=2×10−5) with an increased risk of coronary artery disease
(CAD) [36].
Of the 11 AGEs and collagen cross-linking variables
assayed, rs1495741 was nominally associated with G-H1 in
the same direction as with SF. G-H1 is a hydroimidazolone
derived from arginine residues modified by glyoxal, a potent
glycating agent [40]. G-H1 itself is not fluorescent, but its
reactive AGE precursor, glyoxal, can participate in the forma-
tion of fluorescent structures such as vesperlysine A, which is
detected at 370 nm/440 nm excitation/emission [41]. In the
DCCT, G-H1 was positively associated with age, but not with
duration of diabetes or with recent or long-term HbA1c levels
[6]. Finally, on its own, G-H1 was not significantly associated
with risk of any of the microvascular complications in the
DCCT [6]. Although G-H1 was not correlated with SIF1
measured 15 years later (ESM Table 9), this may be due to
its half-life of 2–6 weeks [40]. Replication of the association
of NAT2 with G-H1 is needed in individuals with diabetes, as
is a determination of the association in those without diabetes.
We used SIF1 for our GWAS in the DCCT/EDIC cohort
based on previous observations that SIF1 had the strongest
association with complications [15, 18] and was closest to the
excitation wavelength used in the LifeLines study. However,
SF measures can be obtained from a wide range of excitation/
emission spectra, which reflect different fluorophores [8, 42].
For example, SF measured with 370 nm/440 nm excitation/
emission has been shown to capture AGEs in general and has
been shown to correlate with pentosidine levels determined by
skin biopsy [42]. The less studied 440 nm/520 nm excitation/
emission fluorescence, which closely corresponds with SIF12,
correlated with pentosidine as well as withNε-carboxymethyl-
lysine, carboxyethyl-lysine and methionine sulphoxide [42].
However, NAT2 was not associated with these AGEs in the
DCCT skin biopsy substudy. Thus, our observation of a
stronger association for NAT2 with SIF12 in the
DCCT/EDIC cohort may also reflect other AGEs that are
possibly associated with elastin–collagen cross-links detected
in response to excitation at higher wavelengths [42]. SIF12,
however, also coincides with non-AGE fluorophores in-
cluding flavin adenine dinucleotide and oxidised flavin
mononucleotide [10], as well as phospholipids, and there-
fore the NAT2 signal for SIF12 may occur through non-
AGE mechanisms [43]. Follow-up studies are needed to
determine the compounds responsible for the association
between NAT2 and SF.
N-Acetyltransferase 2 (NAT2) is known to metabolise
drugs and carcinogens, but no known endogenous substrates
have been identified [44]. A previous GWAS identified an
association of rs1495741 with bladder cancer risk, with sig-
nificant evidence for a gene-by-smoking interaction [45].
However, we observed no such heterogeneity of effect for
rs1495741 on SIF1 by smoking status. NAT2 has also been
identified in several other GWASs, including those involving
plasma [46] and urine metabolites [47] as well as lipids [36].
In both the previous meta-GWAS [36] and the DCCT, the fast
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acetylator G-allele was associated with higher triacylglycerol
levels. Unlike the previous study of primarily individuals
without diabetes [36], rs1495741 was associated with lower
HDL-cholesterol values among fast acetylators in the DCCT
cohort (Table 3, ESM Table 10). Importantly, the effect of
rs1495741 on SIF1 was unchanged after adding time-
weighted mean triacylglycerol or HDL-cholesterol to M3,
arguing that the genetic effect on SF is not mediated by
triacylglycerol or HDL-cholesterol. Themechanism(s) linking
the fast NAT2 acetylator genotype with both elevated triacyl-
glycerol levels and CAD is unknown [36]. However, the
opposing direction of effect of rs1495741 on SF in compari-
son to triacylglycerol, CAD and possibly glycaemic traits [37,
38] suggests that multiple underlying pathways may exist.
The LifeLines study used the AGE Reader to measure SAF
with a peak excitation of 370 nm, compared with SIF1 mea-
sured in the DCCT/EDIC study using the SCOUT DS with
an excitation peak at 375 nm, and different corrections were
made for skin pigmentation. Despite this limitation, the NAT2
regionwas robustly the top signal associatedwith both SIF1 in
the DCCT/EDIC and SAF in the LifeLines cohort. Accordingly,
in the DCCT/EDIC cohort, a correlation of rpearson=0.69
(p10−15) was observed for SIF1 with a proxy for SAF (LED
375 nm, kx=1.0, km=0.0), showing that SIF and SAF are
comparable measurements. NAT2 was not significantly associ-
atedwith SIF1 in the LonGenity study (p=0.09), possibly due to
the age of this cohort, given that collagen production is altered
with older age [48]. However, it was associated with SIF14.
Although NAT2 activity and protein levels have not been de-
tected in normal human dermal fibroblasts [49], the metabolism
of substrates by NAT2 in the liver or colonmay contribute to the
differences in SF between slow and fast acetylators [44, 50].
Finally, since not all AGEs fluoresce, a GWAS of SF may not
identify loci specific to the production or detoxification of non-
fluorescent AGEs, unless they are highly correlated with a
fluorophore in the skin.
In conclusion, using a GWAS, our study demonstrates that
genetic variation contributes to SF, and that NAT2 is a major
locus observed across four independent studies. Although
NAT2 was not significantly associated with the risk of com-
plications of type 1 diabetes, larger studies are needed. NAT2
may improve the screening properties of SF in predicting the
risk of complications or impaired glucose tolerance [14–18].
The robust association observed for NAT2with SF in multiple
cohorts provides proof of principle that genetic variation
contributes to the variance in SF.
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